Can epigenetic changes explain the strong link between age and cancer?

The Eu­ro­pean Med­i­cines Agency is con­cerned there could be a po­ten­tial link be­tween thy­roid can­cer and the use of glucagon-like pep­tide-1 (GLP-1) re­cep­tor ag­o­nists, which

Citius Phar­ma­ceu­ti­cals plans to re­file its ex­per­i­men­tal drug for a rare blood can­cer in ear­ly 2024 fol­low­ing an FDA re­jec­tion in Ju­ly. The drug, Lym­phir,

Eli Lilly, BMS, and Novartis have all conducted billion-dollar deals to claim a stake in the promising radiopharma space. Image credit: Shutterstock / Love Employee.